Key Takeaways
- • Nervonik closed an oversubscribed $52.5 million Series B financing led by Amzak Health, with participation from five additional institutional investors including U.S. Venture Partners, Elevage Medical Technologies, Lumira Ventures, Foothill Ventures, and Shangbay Capital.
- • The clinical-stage medical device company is advancing next-generation peripheral nerve stimulation (PNS) technologies that integrate real-time physiological feedback and proprietary sensing capabilities to enable more precise, personalized therapy for chronic pain treatment.
- • Capital will accelerate clinical program development, prepare for commercialization, and support further advancement of proprietary sensing capabilities, positioning Nervonik as a differentiated player in the neuromodulation market.
- • Early clinical data demonstrate successful recording of evoked compound action potentials (ECAPs) and other biomarkers using implantable leads, establishing technical proof-of-concept for the company's bioelectronic medicine platform.
- • The financing occurs amid expanding clinical evidence and growing adoption of peripheral nerve stimulation therapies for chronic pain management, suggesting favorable market conditions for device innovation in this therapeutic category.
Summary
Nervonik, Inc., a Los Angeles-based clinical-stage medical device company, announced the closing of a $52.5 million Series B financing on April 27, 2026. The oversubscribed round was led by Amzak Health and included participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital, reflecting broad institutional investor confidence in the company's peripheral nerve stimulation platform.
The company is developing differentiated neuromodulation technology that combines electrical stimulation with advanced sensing capabilities to deliver real-time physiological feedback and personalized therapy. According to CEO and Founder Aydin Babakhani, Nervonik's "fundamentally differentiated" platform integrates sensing with stimulation to enhance precision and efficacy in therapeutic delivery. Early clinical data have demonstrated successful recording of evoked compound action potentials (ECAPs) and other biomarkers using implantable leads, validating the company's technical approach to bioelectronic medicine.
Capital from the Series B will support continued development and commercialization of Nervonik's proprietary PNS system, including advancement of its sensing capabilities, acceleration of clinical programs, and preparation for market entry. Anthony Natale, MD, Partner at lead investor Amzak Health, noted that "peripheral nerve stimulation is at an inflection point, with expanding clinical evidence and growing adoption in the treatment of chronic pain," underscoring favorable market fundamentals for the company's technology. The financing positions Nervonik to capitalize on this market expansion during a critical period of clinical validation and regulatory pathway development.
The company is developing differentiated neuromodulation technology that combines electrical stimulation with advanced sensing capabilities to deliver real-time physiological feedback and personalized therapy. According to CEO and Founder Aydin Babakhani, Nervonik's "fundamentally differentiated" platform integrates sensing with stimulation to enhance precision and efficacy in therapeutic delivery. Early clinical data have demonstrated successful recording of evoked compound action potentials (ECAPs) and other biomarkers using implantable leads, validating the company's technical approach to bioelectronic medicine.
Capital from the Series B will support continued development and commercialization of Nervonik's proprietary PNS system, including advancement of its sensing capabilities, acceleration of clinical programs, and preparation for market entry. Anthony Natale, MD, Partner at lead investor Amzak Health, noted that "peripheral nerve stimulation is at an inflection point, with expanding clinical evidence and growing adoption in the treatment of chronic pain," underscoring favorable market fundamentals for the company's technology. The financing positions Nervonik to capitalize on this market expansion during a critical period of clinical validation and regulatory pathway development.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.